Darolutamide is a non-steroidal androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer. To support rigorous pharmaceutical analysis, this category… Read more































Darolutamide is a non-steroidal androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer. To support rigorous pharmaceutical analysis, this category encompasses a comprehensive collection of Darolutamide reference standards, including the active pharmaceutical ingredient, synthesis-related impurities, degradation products, stereoisomers, and metabolites. Laboratories utilize these high-quality materials for impurity profiling, method validation, and routine quality control to ensure regulatory compliance. The inclusion of stable isotope labelled compounds provides essential tools for internal standard calibration in mass spectrometry, facilitating precise quantification during stability studies and bioanalytical assays. By offering access to pharmacopeial and non-pharmacopeial impurities, as well as structurally characterized degradation products formed through pathways like hydrolysis and oxidation, this collection supports the entire drug development lifecycle, ensuring the potency, safety, and stability of pharmaceutical formulations throughout their shelf life.